Merck may see a surge in Vioxx lawsuits after an independent study found an increased risk of kidney-related complications and arrhythmia, a JP Morgan Securities analyst believes.

A data analysis of 114 clinical trials involving more than 116,000 patients found that Merck’s (nyse: MRK – news – people ) withdrawn painkiller was associated with an increased risk of “renal events,” which include swelling of the hands and feet, high blood pressure and kidney dysfunction..

The study was conducted by researchers at Harvard University and published online late Tuesday by The Journal of the American Medical Association.

With the statutes of limitations expiring soon for many former patients, JP Morgan pharmaceuticals analyst Chris Shibutani said the studies may prompt many to “pile on” the tens of thousands of Vioxx-related lawsuits already filed against Merck.

“Since few plaintiffs with renal injuries or arrhythmias have likely considered pursuing a Vioxx suit to date, this study may provide the motivation to file,” Shibutani wrote in a note sent to clients Wednesday.

A separate review conducted by medical researchers from Australia confirmed the early association between Vioxx and heart attack risks and indirectly raised concerns about Merck’s Vioxx successor drug, Arcoxia.

The Australian researchers found that Pfizer’s (nyse: PFE – news – people ) competing Celebrex, when taken in normal doses, may not increase the risk of heart attacks and stroke and raised “serious questions about the safety of diclofenac,” an older drug also known as Voltaren. Data from a recent study of Arcoxia showed a risk profile similar to Voltaren’s.

The JP Morgan analyst said the studies were a “moderate negative” for Merck and could provide “extra ammunition” for lawyers.

“We expect that plaintiffs’ attorneys will be adding references to this study to the materials they use to bring in new product-liability clients,” he said. “The results will give plaintiffs an extra arrow in their litigation quiver, and could encourage the filing of suits by plaintiffs who previously believed their cases were too weak.”

Shibutani maintained a “neutral” rating on Merck shares, which tumbled $1.12, or almost 3%, to $41.03 in early afternoon trading.



We're here to help!

We live by our creed of "helping those who need it most" and have helped thousands of clients get the justice they desperately needed and deserved. If you feel you have a case or just have questions please contact us for a free consultation. There is no risk and no fees unless we win for you.

Fields marked    may be required for submission.
  1. I'm an attorney

Merck to pay $830 million to settle investors’ Vioxx...

Merck announced Friday it will pay $830 million to settle investor complaints accusing it of committing...

Merck to pay nearly $1 billion for illegal marketing...

American pharmaceutical company Merck, Sharp & Dohme has agreed to pay $950 million to resolve criminal...

Merck paying more than 3,100 vioxx death claims

Merck & Co. is paying claims by the families of more than 3,100 users of its Vioxx painkiller who...

Settlement limits insurers' claims in Vioxx deal

TRENTON, N.J. (AP) -- Former Vioxx users getting part of a $4.85 billion settlement ending most personal...

Persistence pays in Vioxx litigation

Plaintiffs get close to $5B, but Merck could have done a lot worse. Attorneys who spent nearly one year...

Vioxx settlement payments to begin in August

Merck & Co., manufacturer of Vioxx, announced it will make the first payment of $500 million on Aug....

I never dreamed how much this would mean to me

I received another check today, much to my surprise. Thank you, thank you, thank you! I never dreamed how much this would mean to me in my golden years, as I have had hearing problems for years and needed to update my hearing aids, but with a limited income, found that was impossible. I now have the best hearing aids that I have ever had, thanks to you fighting so hard on my behalf.

—Gladys